Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GD2-GD3 vaccine |
Synonyms | |
Therapy Description |
GD2-GD3 vaccine is a bivalent vaccine that comprises the epitopes of the gangliosides GD2 and GD3, which are conjugated to keyhole limpet hemocyanin, thereby potentially resulting in an immune response against tumor cells expressing GD2 and GD3 (PMID: 24520094). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GD2-GD3 vaccine | GD2-GD3 vaccine is a bivalent vaccine that comprises the epitopes of the gangliosides GD2 and GD3, which are conjugated to keyhole limpet hemocyanin, thereby potentially resulting in an immune response against tumor cells expressing GD2 and GD3 (PMID: 24520094). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00911560 | Phase Ib/II | Beta-glucan GD2-GD3 vaccine | Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral beta-glucan for High-Risk Neuroblastoma | Active, not recruiting | USA | 0 |